Agios Pharmaceuticals
AGIO
144 hedge funds and large institutions have $1.46B invested in Agios Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 56 increasing their positions, 46 reducing their positions, and 17 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.02% less ownership
Funds ownership: 106.81% → 105.79% (-1%)
5% less funds holding
Funds holding: 152 → 144 (-8)
13% less capital invested
Capital invested by funds: $1.68B → $1.46B (-$216M)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
48% less call options, than puts
Call options by funds: $6.15M | Put options by funds: $11.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11.2M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.66M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.8M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$7.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$17.6M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$10.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.4M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$5.37M |
| 5 |
Man Group
London,
United Kingdom
|
-$4.51M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCM
151
Graham Capital Management
Rowayton,
Connecticut
| – | -$480K | -16,958 | Closed |
|
152
Franklin Resources
San Mateo,
California
| – | -$284K | -10,021 | Closed |
|
|
EFM
153
E Fund Management
Guangzhou,
China
| – | -$249K | -8,793 | Closed |
|
154
AQR Capital Management
Greenwich,
Connecticut
| – | -$217K | -7,717 | Closed |
|
155
Parallax Volatility Advisers
San Francisco,
California
| – | -$59.5K | -2,102 | Closed |
|
|
HIA
156
Harbor Investment Advisory
Lutherville,
Maryland
| – | -$38.9K | -1,375 | Closed |
|
|
VCM
157
Versant Capital Management
Phoenix,
Arizona
| – | -$1.81K | -64 | Closed |
|
|
TFP
158
Tilia Fiduciary Partners
Wilmington,
North Carolina
| – | -$1.08K | -38 | Closed |
|
|
DI
159
Disciplined Investments
Tulsa,
Oklahoma
| – | -$57 | -2 | Closed |
|
|
C
160
Covestor
London,
United Kingdom
| – | +$106 | +4 | +80% |
|
|
SFG
161
Steward Financial Group
Colleyville,
Texas
| – | +$238 | +9 | New |
|
AGIO Hedge Fund Activity: Q3 2023 in Review
144 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2023, worth a combined $1.46B — down 13% from $1.68B a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AGIO and 10 opened new positions — a net loss of 7 holders — while 46 trimmed existing stakes and 56 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $11.2M. The largest seller was Wellington Management Group, cutting an estimated $17.6M.
- 144 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2023, down from 152 in Q2 2023.
- Funds reported $1.46B of Agios Pharmaceuticals stock for Q3 2023, down 13% quarter-over-quarter.
- 10 funds opened new Agios Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of -7 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2023 was Deep Track Capital, an estimated $11.2M added.
- The largest Agios Pharmaceuticals seller in Q3 2023 was Wellington Management Group, an estimated $17.6M sold.
Based on aggregated 13F filings for Q3 2023.